Herantis Pharma Plc (HRTIS):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Herantis Pharma Plc (HRTIS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8206
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:42
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フィンランド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Herantis Pharma Plc (Herantis Pharma) is a drug development company that offers regenerative medicine for neurodegenerative diseases. The company’s pipeline products include CDNF for amyotrophic lateral sclerosis, CDNF for Parkinson’s disease and lymfactin for secondary lymphedema. Its lymfactin recovers the damaged lymph system by reconstituting lymphatic vasculature. Herantis Pharma offers CDNF for disease modification in neurodegenerative diseases such as Parkinson’s and ALS. The company develops drug candidates through late pre-clinical and early clinical stages. It partners with pharmaceutical and biotech companies. Herantis Pharma is headquartered in Espoo, Finland.

Herantis Pharma Plc (HRTIS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Herantis Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Herantis Pharma Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Herantis Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Herantis Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Herantis Pharma Plc, Medical Devices Deals, 2012 to YTD 2018 9
Herantis Pharma Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Herantis Pharma Plc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Herantis Pharma Enters into Agreement with Renishaw 11
Merger 12
Hermo Pharma Merges with Laurantis Pharma 12
Licensing Agreements 13
Herantis Pharma Enters into Licensing Agreement with University of Helsinki 13
Equity Offering 14
Herantis Pharma Plans to Raise up to USD5.4 Million in Private Placement of Shares 14
Herantis Pharma Raises USD0.3 Million in Private Placement of Shares 15
Herantis Pharma Raises USD20 Million in IPO 16
Herantis Pharma Plc – Key Competitors 17
Herantis Pharma Plc – Key Employees 18
Herantis Pharma Plc – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Recent Developments 20
Financial Announcements 20
Aug 29, 2018: Herantis Pharma’s half year financial report January 1 – June 30, 2018 20
Mar 02, 2018: Herantis Pharma Financial Statements Release January 1 – December 31, 2017 24
Aug 29, 2017: Herantis Pharma: half year financial report January 1 – June 30, 2017 27
Feb 28, 2017: Herantis Pharma Financial Statements Release January 1-December 31, 2016 31
Government and Public Interest 34
Apr 19, 2018: Herantis Pharma awarded Innovation prize of the Chemical Industry Federation of Finland 34
Product News 35
06/22/2017: Herantis Pharmas Lymfactin study advances to last patient cohort, company announces initial plans for continued development 35
02/12/2018: Herantis Pharma strengthens team – Outi Lahdenpera and Antti Vuolanto have joined Herantis 36
Clinical Trials 37
Jun 13, 2018: Herantis Pharma announces initiation of Phase 2 study for Lymfactin gene therapy in secondary lymphedema 37
Apr 16, 2018: Herantis Pharma announces positive interim data from Lymfactin study in secondary lymphedema 38
Feb 08, 2018: Herantis Pharma completes patient enrolment in Phase 1 study of Lymfactin gene therapy for secondary lymphedema and has submitted Phase 2 application 39
Dec 27, 2017: Herantis Pharma expands on timeline for Lymfactin studies 40
Mar 06, 2017: Herantis Pharma’s clinical study with Lymfactin advances to high dose level 41
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42

List of Tables
Herantis Pharma Plc, Pharmaceuticals & Healthcare, Key Facts 2
Herantis Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Herantis Pharma Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Herantis Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Herantis Pharma Plc, Deals By Therapy Area, 2012 to YTD 2018 8
Herantis Pharma Plc, Medical Devices Deals, 2012 to YTD 2018 9
Herantis Pharma Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Herantis Pharma Enters into Agreement with Renishaw 11
Hermo Pharma Merges with Laurantis Pharma 12
Herantis Pharma Enters into Licensing Agreement with University of Helsinki 13
Herantis Pharma Plans to Raise up to USD5.4 Million in Private Placement of Shares 14
Herantis Pharma Raises USD0.3 Million in Private Placement of Shares 15
Herantis Pharma Raises USD20 Million in IPO 16
Herantis Pharma Plc, Key Competitors 17
Herantis Pharma Plc, Key Employees 18
Herantis Pharma Plc, Other Locations 19
Herantis Pharma Plc, Subsidiaries 19

List of Figures
Herantis Pharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Herantis Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Herantis Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Herantis Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Herantis Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Herantis Pharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Herantis Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Herantis Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Herantis Pharma Plc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Herantis Pharma Plc (HRTIS):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Gulfport Energy Corp Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Gulfport Energy Corp Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Gulfport Energy Corp (Gulfport) is an oil and gas company that explores, develops and produces oil and natural gas. The company operates its oil and gas exploration and development assets in Uti …
  • Umeme Limited (UMEME):企業の財務・戦略的SWOT分析
    Umeme Limited (UMEME) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Aker Solutions ASA (AKSO):石油・ガス:M&Aディール及び事業提携情報
    Summary Aker Solutions ASA (Aker Solutions) is a global provider of engineering, design, production systems and services to the oil and gas industry. The company offers subsea production equipment and offshore field design, ranging from concept studies and front-end engineering to subsea production …
  • Mitsubishi Materials Corporation:企業のM&A・事業提携・投資動向
    Mitsubishi Materials Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Mitsubishi Materials Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on merge …
  • Equity Assurance plc:企業の戦略・SWOT・財務情報
    Equity Assurance plc - Strategy, SWOT and Corporate Finance Report Summary Equity Assurance plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Oman Telecommunications Company SAOG:企業の戦略・SWOT・財務情報
    Oman Telecommunications Company SAOG - Strategy, SWOT and Corporate Finance Report Summary Oman Telecommunications Company SAOG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Lexmark International Inc:医療機器:M&Aディール及び事業提携情報
    Summary Lexmark International Inc (Lexmark) a subsidiary of Ninestar Corp., provider of imaging and printing solutions. It manufactures, develops and supplies printing and imaging solutions, managed print services, device management, document workflow, business process and content management solutio …
  • University of British Columbia-製薬・医療分野:企業M&A・提携分析
    Summary University of British Columbia (UBC) is a research institute that offers educational services. The university provides undergraduate, graduate educational programs, and research programs through its schools and faculties. It provides cultural, recreational and social activities for its stude …
  • Nan Ya Plastics Corporation:企業の戦略・SWOT・財務分析
    Nan Ya Plastics Corporation - Strategy, SWOT and Corporate Finance Report Summary Nan Ya Plastics Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • HumanOptics AG (H9O1):企業の財務・戦略的SWOT分析
    Summary HumanOptics AG (HumanOptics), a subsidiary of Medipart AG, is a medical device company that develops, manufactures and distributes intraocular implants for opthalmic surgeries. The company offers products such as intraocular lenses, artificiallris, capsular tension rings and cornea implants. …
  • AXA Life Insurance Co., Ltd.:企業の戦略・SWOT・財務情報
    AXA Life Insurance Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary AXA Life Insurance Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • A. K. Capital Services Ltd (530499):企業の財務・戦略的SWOT分析
    A. K. Capital Services Ltd (530499) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Boursorama SA:企業の戦略・SWOT・財務情報
    Boursorama SA - Strategy, SWOT and Corporate Finance Report Summary Boursorama SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Secom Co., Ltd.:企業の戦略・SWOT・財務情報
    Secom Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Secom Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Chiesi USA Inc:企業の戦略的SWOT分析
    Chiesi USA Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Shandong Weigao Group Medical Polymer Company Ltd (1066):企業の財務・戦略的SWOT分析
    Shandong Weigao Group Medical Polymer Company Ltd (1066) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company …
  • GAIL (India) Ltd (GAIL)-エネルギー分野:企業M&A・提携分析
    Summary GAIL (India) Ltd (GAIL) is a vertically integrated gas company that carries out exploration and production, transmission of natural gas. It also has presence in petrochemical, liquid hydrocarbons and power and renewable sectors. GAIL is also a major LPG transmission company, besides managing …
  • PT Medco Energi Internasional Tbk (MEDC):電力:M&Aディール及び事業提携情報
    Summary PT Medco Energi Internasional Tbk (MedcoEnergi), a subsidiary of Encore Energy Pte. Ltd., is an integrated energy company. It explores for and develops oil and gas fields. The company provides energy related services such as power production, engineering procurement and construction (EPC), o …
  • Synopsys Inc (SNPS):企業の財務・戦略的SWOT分析
    Synopsys Inc (SNPS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Can-Fite BioPharma Ltd (CANF):企業の財務・戦略的SWOT分析
    Summary Can-Fite BioPharma Ltd (Can-Fite) is a clinical stage drug development Company that strives to develop small molecule drugs for the treatment of cancer and inflammatory diseases. The company’s pipeline products which are in phase II and III clinical development stage includes CF101, for rheu …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆